Emerald Health Therapeutics Inc. (EMHTF) Return on Investment ROI from the fourth quarter of 2019 to fourth quarter of 2018 and for the year 2019, average high and low, overall ranking from Dec 31 2019 to Dec 31 2018 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Emerald Health Therapeutics Inc.  (EMHTF)


Emerald Health Therapeutics's ROI from its fourth quarter of 2019 to the fourth quarter of 2018 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Emerald Health Therapeutics's ROI in the fourth quarter of 2019?
Emerald Health Therapeutics Inc. achieved a return on average invested assets (ROI) of 334.8 % in its fourth quarter of 2019, which is below Emerald Health Therapeutics's average return on investment, which stands at 392.21%.

ROI has improved compared to 43.83% in the third quarter of 2019, due to net income growth.

Within the Healthcare sector 4 other companies had a higher return on investment. While the total ranking for ROI remained the same, compared to the third quarter of 2019 at no. .

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2019)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2018)
IV. Quarter
Y / Y Investment Change TTM 2066.69 % 20.1 % -16.88 % -54.58 % -93.02 %
Y / Y Net Income Change TTM 562.36 % - - - -
Investment (TTM) in Millions 17 22 22 22 2
Return On Investment (TTM) 334.8 % 43.83 % 135.44 % 186.48 % 1095.2 %
EMHTF's Overall Ranking # # # # #
Seq. Investment Change TTM 22.34 % 45.88 % 84.78 % 556.99 % -93.22 %
Seq. Net Income Change TTM 834.54 % -52.79 % 34.2 % 11.87 % -
Net Income (TTM) in Millions 69 7 16 12 10

EMHTF Company Profile >> Back to EMHTF Roi Comparisons >> See Annual EMHTF Return On Investment



Return On Investment EMHTF's Ranking
Within: No.
Industry # 2
Sector # 5
Overall #

Return On Investment Statistics
High Average Low
392.21 %
392.21 %
392.21 %
(Dec 31 2019)  







Financial Statements
Emerald Health Therapeutics's IV. Quarter Investments $ 17 Millions EMHTF's Balance sheet
Emerald Health Therapeutics's IV. Quarter Income $ 86 Millions Quarterly EMHTF's Income Statement
EMHTF's Income by Division See EMHTF's Income by Division


EMHTF Annual Return On Investment (Dec 31 2019)
2019		 (Dec 31 2018)
2018


Total Investments in Millions 22 1 0 0 0
Y / Y Investment Growth 3973.78 % - - - -
Net Income in Millions 86 24 0 0 0
Y / Y Net Income Growth 261.18 % - - - -
Annual Return On Investment 392.21 % 4423.73 % - - -


Annual Roi Comment
In the fiscal year 2019 ROI deteriorated to 392.21 %, despite net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
EMHTF's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for EMHTF's Competitors
Subscribers only: Roi for Emerald Health Therapeutics's Suppliers
Subscribers only: Return On Investment for EMHTF's Customers

Other Ratios
EMHTF's Roa EMHTF's Inventory Turnover Ratio EMHTF's Growth Rates EMHTF's Dividend Statistics
EMHTF's Profitability Ratios EMHTF's Asset Turnover Ratio EMHTF's Dividend Growth
EMHTF's Roe EMHTF's Valuation Ratios EMHTF's Financial Strength Ratios EMHTF's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2019, within Healthcare Sector ROI
Zomedica Corp   611.96 %
Tuhura Biosciences Inc   489.26 %
Exagen Inc   472.18 %
Oyster Point Pharma Inc   457.62 %
Black Diamond Therapeutics Inc   398.87 %
Emerald Health Therapeutics Inc.  392.21 %
Trillium Therapeutics Inc   359.16 %
Xbiotech Inc   288.29 %
Progyny Inc   282.27 %
Check Cap Ltd  208.78 %
Quoin Pharmaceuticals Ltd   166.78 %
Semler Scientific inc   152.40 %
Collplant Biotechnologies Ltd  150.34 %
Tenax Therapeutics Inc   113.26 %
Rapt Therapeutics Inc   98.39 %
Altamira Therapeutics Ltd   89.97 %
Morphic Holding inc   84.53 %
Jounce Therapeutics inc   69.85 %
Orgenesis Inc   68.81 %

Date modified: 2026-09-08T15:09:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.